Fibroblast growth factor-23 (FGF-23) levels differ across populations by degree of industrialization

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 5, 2016, Pages 2246-2253

  Yuen, Shennin N ^a   Holly, Kramer ^a,b   Luke, Amy ^a   Bovet, Pascal ^c,d   Plange Rhule, Jacob ^e   Forrester, Terrence ^f   Lambert, Vicki ^g   Wolf, Myles ^h   Camacho, Pauline ^b   Harders, Regina ^a   Dugas, Lara ^a   Cooper, Richard ^a   Durazo Arvizu, Ramon ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d MINISTRY OF HEALTH   (Seychelles)

^e KWAME NKRUMAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Ghana)

^f UNIVERSITY OF THE WEST INDIES   (Jamaica)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

^h Northwestern Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PHOSPHATE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; FEMALE; GEOGRAPHIC DISTRIBUTION; GHANA; HUMAN; INDUSTRIALIZATION; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; PHOSPHATE INTAKE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; SEX DIFFERENCE; SEYCHELLES; UNITED STATES; URINARY EXCRETION; BLOOD; CROSS-SECTIONAL STUDY; DIET;

ADULT; BIOMARKERS; CROSS-SECTIONAL STUDIES; DIET; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; INDUSTRIAL DEVELOPMENT; MALE; MIDDLE AGED; PHOSPHATES;

EID: 84969844624     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-3558     Document Type: Article

References (36)

1. Houston J, Isakova T, Wolf M. Phosphate metabolism and fibroblast growth factor 23 in chronic kidney disease. In:Kopple JD, Massry SG, Kalantar-Zadeh K, eds. Nutritional Management of Renal Disease. 3rd ed. London: Academic Press; 2013:285-308.
2. Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na+ dependent phosphate co-transport activity and 1α, 25-dihydroxyvitamin D3 production. J Biol Chem. 2004;278:2206-2211.
3. Shimada T, Hasegawa H, Yamazaki Y, et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res. 2003;19:429.
4. Shimada T, Muto T, Urakawa I, et al. Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. Endocrinology. 2002;143(8):3179-3182.
5. Abramowitz M, Muntner P, Coco M, et al. Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol. 2010;5(6):1064-1071.
6. Dhingra R, Gona P, Benjamin EJ, et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail. 2010; 12(8):812-818.
7. Uribarri J, Calvo MS. Hidden sources of phosphorus in the typical American diet: does it matter in nephrology? Semin Dial. 2003; 16(3):186-188.
8. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the Health Professionals Follow-up Study. Clin J Am Soc Nephrol. 2011;6(12):2871-2878.
9. Houston J, Smith K, Isakova T, Sowden N, Wolf M, Gutierrez OM. Associations of dietary phosphorus intake, urinary phosphate excretion, and fibroblast growth factor 23 with vascular stiffness in chronic kidney disease. J Renal Nutr. 2013;23(1):12-20.
10. Burnett SM, Gunawardene SC, Bringhurst FR, Juppner H, Lee H, Finkelstein JS. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J Bone Miner Res. 2006;21(8): 1187-1196.
11. Antoniucci DM, Yamashita T, Portale AA. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006;91(8):3144-3149.
12. Ferrari SL, Bonjour JP, Rizzoli R. Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab. 2005;90(3):1519-1524.
13. Ix JH, Chonchol M, Laughlin GA, Shlipak MG, Whooley MA. Relation of sex and estrogen therapy to serum fibroblast growth factor 23, serum phosphorus, and urine phosphorus: the Heart and Soul Study. Am J Kidney Dis. 2011;58(5):737-745.
14. Takeda E, Yamamoto H, Yamanaka-Okumura H, Taketani Y. Increasing dietary phosphorus intake from food additives: potential for negative impact on bone health. Adv Nutr. 2014;5(1):92-97.
15. Bell RR, Draper HH, Tzeng DY, Shin HK, Schmidt GR. Physiological responses of human adults to foods containing phosphate additives. J Nutr. 1977;107(1):42-50.
16. Sullivan CM, Leon JB, Sehgal AR. Phosphorus-containing food additives and the accuracy of nutrient databases: implications for renal patients. J Renal Nutr. 2007;17(5):350-354.
17. Gutierrez OM. Sodium- and phosphorus-based food additives: persistent but surmountable hurdles in the management of nutrition in chronic kidney disease. Adv Chronic Kidney Dis. 2013;20(2):150-156.
18. Eckberg K, Kramer H, Wolf M, et al. Impact of Westernization on fibroblast growth factor 23 levels among individuals of African ancestry. Nephrol Dial Transplant. 2015;30(4):630-635.
19. The World Bank. http://beta.data.worldbank.org. Washington, DC.
20. Luke A, Bovet P, Forrester TE, et al. Protocol for the modeling the epidemiologic transition study: a longitudinal observational study of energy balance and change in body weight, diabetes and cardiovascular disease risk. BMC Public Health. 2011;11:927.
21. Clinkenbeard EL, Farrow EG, Summers LJ, et al. Neonatal iron deficiency causes abnormal phosphate metabolism by elevating FGF23 in normal and ADHR mice. J Bone Miner Res. 2014;29(2): 361-369.
22. Braithwaite V, Jarjou LM, Goldberg GR, Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone. 2012;50(6): 1351-1356.
23. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367(1):20-29.
24. Oehlert GW. A note on the delta method. Am Stat. 1992;46(1): 27-29.
25. Durazo-Arvizu RA, Camacho P, Bovet P, et al. 25-Hydroxyvitamin D in African-origin populations at varying latitudes challenges the construct of a physiologic norm. Am J Clin Nutr. 2014;100(3):908-914.
26. di Giuseppe R, Kuhn T, Hirche F, et al. Potential predictors of plasma fibroblast growth factor 23 concentrations: Cross-sectional analysis in the EPIC-Germany study. PLoS One. 2015;10(7): e0133580.
27. Carrillo-Lopez N, Roman-Garcia P, Rodriguez-Rebollar A, Fernandez-Martin JL, Naves-Diaz M, Cannata-Andia JB. Indirect regulation of PTH by estrogens may require FGF23. J Am Soc Nephrol. 2009;20(9):2009-2017.
28. Uemura H, Irahara M, Yoneda N, et al. Close correlation between estrogen treatment and renal phosphate reabsorption capacity. J Clin Endocrinol Metab. 2000;85(3):1215-1219.
29. Miyamura M, Fujita S, Morita H, et al. Circulating fibroblast growth factor 23 has a U-shaped association with atrial fibrillation prevalence. Circ J. 2015;79(8):1742-1748.
30. Hsu HJ, Wu MS. Fibroblast growth factor 23: A possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009;337(2):116-122.
31. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009;205(2):385-390.
32. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009;207(2):546-551.
33. Wright CB, Dong C, Stark M, et al. Plasma FGF23 and the risk of stroke: the Northern Manhattan Study (NOMAS). Neurology. 2014;82(19):1700-1706.
34. Hariharan D, Vellanki K, Kramer H. The Western diet and chronic kidney disease. Curr Hypertens Rep. 2015;17(3):16.
35. Carruthers BM, Copp DH, Mcintosh HW. Diurnal variation in urinary excretion of calcium and phosphate and its relation to blood levels. J Lab Clin Med. 1964;63:959-968.
36. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol. 2010;21(9):1427-1435.